Browse > Article

Development of Probiotic Products and Challenges  

Seo, Jae-Gu (Cell Biotech, Co., Ltd.)
Lee, Gwa-Soo (Cell Biotech, Co., Ltd.)
Kim, Jin-Eung (Cell Biotech, Co., Ltd.)
Chung, Myung-Jun (Cell Biotech, Co., Ltd.)
Publication Information
KSBB Journal / v.25, no.4, 2010 , pp. 303-310 More about this Journal
Abstract
Probiotics beneficially affect the health of the host via various mechanisms in the intestine. Recent developments in probiotic products have mainly been made to maximize probiotic effects in human. In this regard, probiotic products containing doubly coated or encapsulated cells, multi-species probiotics, or high viable cell number (1010 viable cells/gram or more) have been developed and are already available in the market. Until now, the majority of probiotics contain live cells but little attention has been paid to other alternative products such as heat-killed cell or bacteriocin-containing ones, which could have broad applications due to advantages over live cell-based probiotics, such as safety and stability. In addition, genetically engineered lactic acid bacteria could be of great importance in the field of alimentary health if they are carefully designed for biological safety. Although a number of probiotics are marketed by claiming health benefits, regulations for health claims will be more stringent. Therefore sufficient scientific and clinical evidences supporting the safety and efficacy of the potential probiotic strain will be required by the regulatory authority for a health claim, which thus may have a huge impact on the future probiotic market.
Keywords
Probiotics; Lactic acid bacteria; Probiotic effect; European Food Safety Authority; Health claim;
Citations & Related Records
Times Cited By KSCI : 1  (Citation Analysis)
연도 인용수 순위
1 Fasoli, S., M. Marzotto, L. Rizzotti, F. Rossi, F. Dellaglio, and S. Torriani (2003) Bacterial composition of commercial probiotic products as evaluated by PCRDGGE analysis. Int. J. Food Microbiol. 82: 59-70.   DOI   ScienceOn
2 Kruger, C., Y. Hu, Q. Pan, H. Marcotte, A. Hultberg, D. Delwar, P. J. van Dalen, P. H. Pouwels, R. J. Leer, C. G. Kelly, C. van Dollenweerd, J. K. Ma, and L. Hammarström (2002) In situ delivery of passive immunity by lactobacilli producing single-chain antibodies. Nat. Biotechnol. 20: 702-706.   DOI   ScienceOn
3 Hamilton-Miller, J. M. and S. Shah (2002) Deficiencies in microbiological quality and labelling of probiotic supplements. Int. J. Food Microbiol. 72: 175-176.   DOI
4 EFSA panel on Dietetic Products, Nutrition and Allergies (2009) Scientific opinion on the substantiation of health claims related to non-characterised microorganisms pursuant to Article 13(1) of regulation (EC) N0 1924/ 2006. EFSA Journal 7: 1247.   DOI
5 EFSA panel on Dietetic Products, Nutrition and Allergies (2010) Scientific Opinion on the substantiation of health claims related to Bifidobacterium animalis Lafti B94 (CBS118.529) and decreasing potentially pathogenic intestinal microorganisms (ID 867) pursuant to Article 13(1) of Regulation (EC) No 1924/2006. EFSA Journal 7: 1232.
6 EFSA panel on Dietetic Products, Nutrition and Allergies (2009) Scientific Opinion on the substantiation of health claims related to Lactobacillus plantarum 299v (DSM 9843) and decreasing potentially pathogenic intestinal microorganisms (ID 1084) pursuant to Article 13(1) of Regulation (EC) No 1924/2006. EFSA Journal 7: 1242.   DOI
7 Kabak, B. and I. Var (2008) Factors affecting the removal of aflatoxin M1 from food model by Lactobacillus and Bifidobacterium strains. J. Environ. Sci. Health B. 43: 617-624.   DOI   ScienceOn
8 EFSA panel on Dietetic Products, Nutrition and Allergies (2010) Scientific Opinion on the substantiation of health claims related to Lactobacillus plantarum 299v (DSM 9843) and "immune system" (ID 1081), pursuant to Article 13(1) of Regulation (EC) No 1924/2006. EFSA Journal 8: 1488.   DOI
9 Huys, G., M. Vancanneyt, K. D'Haene, V. Vankerckhoven, H. Goossens, and J. Swings (2006) Accuracy of species identity of commercial bacterial cultures intended for probiotic or nutritional use. Res. Microbiol. 157: 803-810.   DOI   ScienceOn
10 The European Union, Regulations (EC) No 1924/2006 of the European Parliament and of the Council of 20 December 2006 on nutrition and health claims made on foods. http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=CELEX:32006R1924R(01):EN:NOT.(2010).
11 Kim, D. and M. J. Chung (2004) A probiotics condensate mixture: Novel antimicrobial application. Nutrafoods 3: 11-16.
12 Kang, B. S., J. G. Seo, G. S. Lee, J. H. Kim, S. Y. Kim, Y. W. Han, H. Kang, H. O. Kim, J. H. Rhee, M. J. Chung, and Y. M. Park (2009) Antimicrobial activity of enterocins from Enterococcus faecalis SL-5 against Propionibacterium acnes, the causative agent in acne vulgaris, and its therapeutic effect. J. Microbiol. 47: 101-109.   과학기술학회마을   DOI
13 Hillman, J. D. (2002) Genetically modified Streptococcus mutans for the prevention of dental caries. Anton. Leeuw. 82: 361-366.   DOI   ScienceOn
14 Lee, Y. K., K. Nomoto, S. Salminen, and S. L. Gorbach. (1999) Handbook of Probiotics. John Wiley & Sons, New York.
15 Drouault, S., C. Juste, P. Marteau, P. Renault, and G. Corthier (2002) Oral treatment with Lactococcus lactis expressing Staphylococcus hyicus lipase enhances lipid digestion in pigs with induced pancreatic insufficiency. Appl. Environ. Microbiol. 68: 3166-3168.   DOI   ScienceOn
16 Lee, Y. K. (2009) Probiotic microorganisms. pp. 3-176. In: Y. K. Lee and S. Salminen (eds.). Handbook of probiotics and prebiotics. John Wiley & Son, Inc., New Jersey, USA.
17 Fuller, R. (1989) Probiotics in man and animal. J. Appl. Bacteriol. 66: 365-378.   DOI
18 Salminen, S., A. Ouwehand, Y. Benno, and Y. K. Lee (1999) Probiotics: how should they be defined? Trends Food Sci. Technol. 10: 107-110.   DOI   ScienceOn
19 Hirose, Y., S. Murosaki, Y. Yamamoto, K. Muroyama, Y. Miwa, A. Fujishima, and B. Lynch (2009) Safety studies of LP20 powder produced from heat-killed Lactobacillus plantarum L-137. Regul. Toxicol. Pharmacol. 54: 214-220.   DOI   ScienceOn
20 Li, N., W. M. Russell, M. Douglas-escobar, N. Hauser, M. Lopez, and J. Neu (2009) Live and heat-killed Lactobacillus rhamnosus GG: effects on proinflammatory and anti-inflammatory cytokines/chemokines in gastrostomyfed infant rats. Pediatr. Res. 66: 203-207.   DOI   ScienceOn
21 Swidsinski, A., A. Ladhoff, Pernthaler, S. Swidsinski, V. Loening-Baucke, M. Ortner, J. Weber, U. Hoffmann, S. Schreiber, M. Dietel, and H. Lochs (2002) Mucosal flora in inflammatory bowel disease. Gastroenterology 122: 44-54.   DOI   ScienceOn
22 Hamilton-Miller, J. M., S. Shah, and J. T. Winkler (1999) Public health issues arising from microbiological and labelling quality of foods and supplements containing probiotic microorganisms. Public Health Nutr. 2: 223-229.
23 Young, V. B. and T. M. Schmidt (2004) Antibioticassociated diarrhea accompanied by large-scale alterations in the composition of the fecal microbiota. J. Clin Microbiol. 42: 1203-1206.   DOI   ScienceOn
24 Temmerman, R., I. Scheirlinck, G. Huys, and J. Swings (2003) Culture in dependent analysis of probiotic products by denaturing gradient gel electrophoresis. Appl. Environ. Microbiol. 69: 220-226.   DOI   ScienceOn
25 Dunne, C., L. Murphy, S. Flynn, L. O'Mahony, S. O'Halloran, M. Feeney, D. Morrissey, G. Thornton, G. Fitzgerald, C. Daly, B. Kiely, E. M. Quigley, G. C. O'Sullivan, F. Shanahan, and J. K. Collins (1999) Probiotics: from myth to reality. demonstration of functionality in animal models of disease and in human clinical trials. Anton. Leeuw. 76: 279-292.   DOI   ScienceOn
26 Rolfe, R. D. (2000) The role of probiotic cultures in the control of gastrointestinal health. J. Nutr. 130: 396S-402S.   DOI
27 Kassinen, A., L. Krogius-Kurikka, H. Makivuokko, T. Rinttilä, L. Paulin, J. Corander, E. Malinen, J. Apajalahti, and A. Palva (2007) The fecal microbiota of irritable bowel syndrome patients differs significantly from that of healthy subjects. Gastroenterology 133: 24-33.   DOI   ScienceOn